160 related articles for article (PubMed ID: 8902056)
41. Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.
Feldman SA; Assadipour Y; Kriley I; Goff SL; Rosenberg SA
Semin Oncol; 2015 Aug; 42(4):626-39. PubMed ID: 26320066
[No Abstract] [Full Text] [Related]
42. [Human tumor-rejection antigens and peptides from genes to clinical research].
Itoh K; Yamana H; Shichijo S; Yamada A
Nihon Geka Gakkai Zasshi; 2000 Sep; 101(9):612-7. PubMed ID: 11022676
[TBL] [Abstract][Full Text] [Related]
43. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
Shilyansky J; Nishimura MI; Yannelli JR; Kawakami Y; Jacknin LS; Charmley P; Rosenberg SA
Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2829-33. PubMed ID: 7511820
[TBL] [Abstract][Full Text] [Related]
44. Tumor-specific T-cell immunity: ready for prime time?
Greenberg PD; Riddell SR
J Natl Cancer Inst; 1992 Jul; 84(14):1059-61. PubMed ID: 1619675
[No Abstract] [Full Text] [Related]
45. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
46. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
Melief CJ
Adv Cancer Res; 1992; 58():143-75. PubMed ID: 1532109
[No Abstract] [Full Text] [Related]
47. Targeting tumours with genetically enhanced T lymphocytes.
Sadelain M; Rivière I; Brentjens R
Nat Rev Cancer; 2003 Jan; 3(1):35-45. PubMed ID: 12509765
[TBL] [Abstract][Full Text] [Related]
48. Adoptive Cellular Therapy (ACT) for Cancer Treatment.
Yang F; Jin H; Wang J; Sun Q; Yan C; Wei F; Ren X
Adv Exp Med Biol; 2016; 909():169-239. PubMed ID: 27240459
[TBL] [Abstract][Full Text] [Related]
49. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
[TBL] [Abstract][Full Text] [Related]
50. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma.
Van den Eynde B; Peeters O; De Backer O; Gaugler B; Lucas S; Boon T
J Exp Med; 1995 Sep; 182(3):689-98. PubMed ID: 7544395
[TBL] [Abstract][Full Text] [Related]
51. Adoptive immunotherapy.
Curti BD
Cancer Chemother Biol Response Modif; 1996; 16():274-84. PubMed ID: 8639385
[No Abstract] [Full Text] [Related]
52. Accumulation of identical T cells in melanoma and vitiligo-like leukoderma.
Becker JC; Guldberg P; Zeuthen J; Bröcker EB; Straten PT
J Invest Dermatol; 1999 Dec; 113(6):1033-8. PubMed ID: 10594748
[TBL] [Abstract][Full Text] [Related]
53. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy.
Boon T
Int J Cancer; 1993 May; 54(2):177-80. PubMed ID: 8486420
[No Abstract] [Full Text] [Related]
54. Human tumor vaccines go molecular. Summary of American Association for Cancer Research Symposium, March 20,1995.
Berd D; Parmiani G
Cancer Immunol Immunother; 1995 Sep; 41(3):199-200. PubMed ID: 7553690
[No Abstract] [Full Text] [Related]
55. A new era for cancer immunotherapy based on the genes that encode cancer antigens.
Rosenberg SA
Immunity; 1999 Mar; 10(3):281-7. PubMed ID: 10204484
[No Abstract] [Full Text] [Related]
56. Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma.
Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Muzikansky A; Kalil J; Festa-Neto C; Duncan LM
J Immunol Res; 2015; 2015():761378. PubMed ID: 25954764
[TBL] [Abstract][Full Text] [Related]
57. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.
Rosenberg SA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S2-7. PubMed ID: 10685650
[No Abstract] [Full Text] [Related]
58. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.
Cohen CJ; Gartner JJ; Horovitz-Fried M; Shamalov K; Trebska-McGowan K; Bliskovsky VV; Parkhurst MR; Ankri C; Prickett TD; Crystal JS; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
J Clin Invest; 2015 Oct; 125(10):3981-91. PubMed ID: 26389673
[TBL] [Abstract][Full Text] [Related]
59. Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-1/Melan-A 27-35 epitope.
Zajac P; Oertli D; Spagnoli GC; Noppen C; Schaefer C; Heberer M; Marti WR
Int J Cancer; 1997 May; 71(3):491-6. PubMed ID: 9139889
[TBL] [Abstract][Full Text] [Related]
60. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells.
Wang HY; Peng G; Guo Z; Shevach EM; Wang RF
J Immunol; 2005 Mar; 174(5):2661-70. PubMed ID: 15728473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
